Evaluation of adiponectin as a risk factor in cardiovascular diseases

ABSTRACT

Cardiovascular disease [CVD] represents one of the worldwide major problems with increasing deaths every year. Diseases like diabetes, hypertension, chronic renal failure and other environmental and genetic factors can compromise the CVD patients. Clinically, the screening and monitoring of CVD requires several biochemical parameters as well as medical ones. Therefore, the purpose of this study is to assay the usefulness of adiponectin as a risk factor in CVD. Adiponectin is synthesized and secreted by the adipose tissue and it was supposed to have anti-inflammatory and anti-hyperlipidemic activity making it a promising risk factor in CVD patients. Here, we examined the associations between plasma levels of adiponectin and body mass index, fasting blood sugar, total cholesterol, HDL-C, LDL-C, triglycerides and hypertension. Forty-three individuals from Ain Shams Specialized Hospital were classified into three groups according to their medical coronary implications, AMI, UAP and SAP, in addition to 15 healthy subjects as a control group. The results indicate a high significant decrease [p < 0.001] in the plasma levels of adiponectin in AMI and UAP compared to the control group. In addition, we found that at AMI, UAP and SAP patients there is a high significant negative correlation between adiponectin and BMI, FBS, total cholesterol, triglycerides and the major cardiac risk factor cTn-T. Also high significant positive correlation with HDL-cholesterol was observed. Therefore, we assume that adiponectin can be a promising risk factor other than the well-known traditional risk factors for cardiovascular disease patients and it can represent a good way to screen CVD through monitoring and assaying its plasma level